NASDAQ: BCPC · Specialty Chemicals
Balchem (BCPC) fair value: undervalued or overvalued?
As of 28 Sep 2026, Faircurve's model values Balchem (BCPC) at $145.50 a share. The stock last closed at $166.56, which puts the model's fair value 12.6% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Balchem Corp.
Faircurve Insights · 28 Sep 2026
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.
On 28 Sep 2026, Faircurve's model found a fair value of $145.50 a share, the midpoint of 2,000 simulations. This was -0.8% from the previous run on 19 Sep 2026, which gave $146.69. The calibrated range over 63 trading days was $122.07 to $177.41, built from the fair value and calibrated weekly against realised prices, holding the price 60% of the time at this horizon. The evidence grade was High.
The business scored 73 out of 100 for overall quality against comparable companies, which included Sensient Technologies Corporation (SXT), Cabot Corp. (CBT), and Eastman Chemical Company (EMN). The stock moved a median of 2.7% around its last 8 earnings reports, ignoring direction.
Written from the figures on this page for the 28 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give BCPC?
The calibrated range for BCPC over 63 trading days is $122.07 to $177.41. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $120.64 to $173.49. In 25% of the simulations the fair value came out above the price the model ran on.
How does BCPC score on business quality?
Balchem's overall quality score is 73 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 88 | 12.6%ROIC | 7.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 43 | 1.04xFCF / net income | 1.18x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 86 | 8.8%Revenue growth, trailing | -1.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 42 | 2.1%Net buybacks / market value | 1.9% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | 0.37xNet debt / EBITDA | 2.70x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 67 | 1.1 ptsEBITDA margin downside volatility, 5y | 1.6 pts |
How does BCPC compare with similar companies?
The companies in specialty chemicals closest to Balchem in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| SXT Sensient Technologies Corporation | $128.59 | $117.86 | -8.3% | Fairly valued |
| CBT Cabot Corp. | $76.95 | $85.36 | +10.9% | Fairly valued |
| EMN Eastman Chemical Company | $64.87 | $70.70 | +9.0% | Fairly valued |
| AVNT Avient Corporation | $41.17 | $38.87 | -5.6% | Fairly valued |
| NEU NewMarket Corporation | $924.06 | $826.50 | -10.6% | Fairly valued |
| WLK Westlake Corporation | $63.50 | $65.89 | +3.8% | Low evidence grade |
| ESI Element Solutions Inc | $37.93 | $30.62 | -19.3% | Overvalued |
| SOLS Solstice Advanced Materials Inc. | $57.70 | $56.70 | -1.7% | Low evidence grade |
When does BCPC report earnings, and how has the stock reacted?
Balchem's next earnings report is scheduled for 20 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 3.5% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How BCPC moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 2.7%.
| Report date | Two session move |
|---|---|
| 31 Jul 2026 | +6.7% |
| 30 Apr 2026 | -6.8% |
| 20 Feb 2026 | +0.4% |
| 21 Oct 2025 | +4.1% |
| 31 Jul 2025 | +0.1% |
| 24 Apr 2025 | -0.4% |
| 21 Feb 2025 | +2.6% |
| 25 Oct 2024 | +2.8% |
Balchem at a glance
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.
- Market value
- $5.4B
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Revenue expected, next twelve months
- $1.2B
- Consensus revenue growth, next fiscal year
- +9.1%
- Analysts with estimates
- 2
- Beta to the US market
- 0.06
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Balchem on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for BCPC was $146.69. As of 28 Sep 2026 it is $145.50, a change of -0.8%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Balchem's valuation
Is Balchem stock undervalued or overvalued?
On Faircurve's model, BCPC reads as Fairly valued as of 28 Sep 2026. The model's fair value is $145.50 a share against a last close of $166.56, a gap of -12.6%.
What is BCPC's fair value?
$145.50 a share as of 28 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $120.64 to $173.49.
What price range does the model give BCPC?
$122.07 to $177.41 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Balchem report earnings next?
The next report is scheduled for 20 Oct 2026. Companies can move their dates.
How much has BCPC moved on past earnings reports?
Across its last 8 reports the median two session move was 2.7%, ignoring direction. The largest was -6.8% around the report of 30 Apr 2026.
How confident is the model in this valuation?
The model's evidence grade for BCPC is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.